Equities

Cyanotech Corp

CYAN:QBB

Cyanotech Corp

Actions
  • Price (USD)0.3988
  • Today's Change0.034 / 9.26%
  • Shares traded5.21k
  • 1 Year change-51.95%
  • Beta0.0021
Data delayed at least 15 minutes, as of Jul 05 2024 15:30 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cyanotech Corporation is an agricultural company, which is engaged in the production of natural products derived from microalgae grown in complex and intricate agricultural systems on the Kona coast of Hawaii. It cultivates, on a large-scale basis, two microalgal species from which its two major product lines, natural astaxanthin products and spirulina products, are derived. Its products include BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica. BioAstin Hawaiian Astaxanthin is a dietary antioxidant shown to support and maintain the body’s natural inflammatory response, to enhance skin, and to support eye, joint and immune health. BioAstin Hawaiian Astaxanthin has expanding applications as a human dietary supplement and dietary ingredient. Hawaiian Spirulina Pacifica is a nutrient-rich dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids. Its products are sold as consumer-packaged goods.

  • Revenue in USD (TTM)23.07m
  • Net income in USD-5.27m
  • Incorporated1980
  • Employees77.00
  • Location
    Cyanotech Corp73-4460 Queen Kaahumanu Hwy, Suite #102KAILUA KONA 96740United StatesUSA
  • Phone+1 (808) 326-1353
  • Fax+1 (808) 329-4533
  • Websitehttps://www.cyanotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SOHM Inc-100.00bn-100.00bn1.76m--------------------------------------------------------------
Link Reservations Inc0.00-480.90k1.80m0.00---------46.51-46.510.00-13.990.00-------246.84-----------------2.43---------22.69------
Nexien Biopharma Inc0.00-246.18k1.85m0.00---------0.0038-0.00380.00-0.00480.00-------679.40-860.53---1,653.53-----------1.77--------42.22------
AgriFORCE Growing Systems Ltd16.28k-13.34m1.87m7.00--0.1811--114.67-10.78-10.780.00390.3960.0009--0.4432,325.71-74.39-78.95-100.77-109.8616.58---81,946.25-243,182.500.8186-1.300.1913------8.85--48.61--
CanaQuest Medical Corp0.00-807.30k1.91m-----------0.0514-0.05140.00-0.0370.00-------1,084.38--------------------------57.42------
cbdMD Inc21.58m-25.65m2.17m52.00--0.5542--0.1006-19.96-19.969.271.010.89492.0921.27415,039.60-89.78-38.59-118.26-41.5062.7063.80-100.33-87.980.6107-3.010.4668---31.77120.9163.64---4.95--
Aoxing Pharmaceutical Company Inc30.11m-1.46m2.42m339.00--0.0283--0.0805-0.0192-0.01920.39510.25070.4962.322.56---2.41-14.54-7.06-35.4576.1968.51-4.85-37.690.73680.33870.6052--26.8837.20-62.49---38.80--
TRACON Pharmaceuticals Inc12.15m1.75m2.55m17.001.46--1.440.20960.65090.65096.27-0.66181.37----714,411.8019.78-79.42---177.85----14.39-813.81---0.4613------32.0587.68------
CYANOTECH CORP23.07m-5.27m2.77m77.00--0.2345--0.1201-0.7996-0.79963.531.700.84141.9013.44299,623.40-19.21-3.46-27.59-4.4625.7634.54-22.83-3.580.3832-6.870.3595---0.4616-5.24-53.11---6.42--
Sonnet Biotherapeutics Holdings Inc92.74k-8.43m2.83m12.00--0.9273--30.54-5.28-5.280.03150.98130.0097--0.22487,728.33-87.68---194.11-------9,086.22-----138.210.00---57.76--36.64------
60 Degrees Pharmaceuticals Inc378.20k-1.07m2.86m2.00------7.55-0.1563-0.15630.05640.61210.04740.88271.90126,066.70-9.87-------23.45---208.43--6.77--0.0217---50.40--35.51------
Scorpius Holdings Inc9.74m-32.20m2.89m82.00--0.0376--0.2962-1.22-1.400.36630.79370.1372--26.56118,815.70-47.81-39.37-58.20-43.1868.56---348.43-1,068.210.2641-198.180.3179--1,789.583.841.96--27.32--
Onconetix Inc758.90k-45.68m3.49m12.00------4.59-2.41-2.410.04071.910.0156--4.7063,241.67-93.67---137.89---123.62---6,019.45--0.2752-17.120.2352-------176.78------
Resonate Blends Inc101.41k-4.72m3.52m6.00------34.71-0.0537-0.05370.0012-0.00070.0328-------152.56-680.29-----34.87-78.88-4,657.83-12,895.26---0.74131.02---66.73-56.57-316.63------
Silo Pharma Inc72.12k-3.53m3.55m3.00--0.5154--49.21-1.18-1.200.0241.870.008----24,040.00-39.26-24.90-43.11-26.3991.9082.79-4,889.57-2,757.85----0.00--0.00--7.07------
Data as of Jul 05 2024. Currency figures normalised to Cyanotech Corp's reporting currency: US Dollar USD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Traphagen Investment Advisors LLCas of 31 Mar 20240.000.00%
G1 Execution Services LLCas of 31 Mar 20240.000.00%
Farther Finance Advisors LLCas of 31 Mar 20240.000.00%
Coastline Trust Co.as of 31 Mar 20240.000.00%
Tower Research Capital LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.